P atients with peripheral artery disease (PAD) are inflicted with widespread atherosclerosis, which imposes a severely increased risk for cardiovascular events and premature mortality. 1 Earlier studies reported a 5-year all-cause mortality rate of 15% to 30% and a recent study of >2.7 million patients with PAD described an even higher all-cause mortality rate of 45% after 3 years. 2, 3 In the latter study, a 3-year incidence of 11% for myocardial infarction and 12% for stroke was observed.
Advanced glycation end products (AGEs) are sugarmodified proteins, nonenzymatically formed during normal life under influence of oxidative and glycemic stress. 4, 5 AGEs have the potential to form irreversible cross-links on long-lived proteins, particularly collagen. The accumulation of AGEs contributes to the stiffness of the myocardium and arteries. 6 Furthermore, binding to specific receptors for AGEs (RAGE) on the endothelial cells promotes cellular stress responses, such as inflammation, thrombosis, and leukocyte recruitment. 4 Consequently, AGEs are involved in the induction and progression of atherosclerosis. 4, 5, [7] [8] [9] [10] April 2014 and mortality in patients with diabetes mellitus, renal insufficiency, and CAD. 8, 13, 14 Recently, we have shown that SAF is increased in patients with PAD independent of conventional cardiovascular risk factors and cardiovascular morbidity. 10 The aim of the present study was to establish whether SAF, as a measure of tissue AGEs deposition, is associated with all-cause mortality and with fatal or nonfatal major adverse cardiovascular events (MACE) in patients with PAD.
Materials and Methods
Materials and Methods are available in the online-only Supplement. In short, we performed a single-center prospective cohort study of 252 patients with established PAD. This cohort consists of the first part of the cohort from our previously reported cross-sectional study on increased SAF in PAD patients.10 Traditional cardiovascular risk factors and the use of lipid-lowering drugs were assessed and deposition of tissue AGEs was noninvasively measured by skin autofluorescence with the AGE Reader. Five year follow-up data were analyzed. The primary endpoint was all-cause mortality. The secondary endpoint was fatal or nonfatal MACE (myocardial infarction, heart failure, stroke, arterial embolism and thrombosis and sudden cardiac death). Time-to-first event was used for both survival analyses. Kaplan-Meier analysis with log-rank test was performed with comparison based on tertiles of SAF. Hazard ratios (HR) with 95% confidence interval (CI) per unit SAF were calculated for both endpoints by Cox regression analysis and repeated with adjustment for confounders. The study was approved by the local institutional review board and all participating patients gave informed consent.
Results

Patients' Characteristics and SAF
A total of 267 patients were willing to participate. Fifteen patients were excluded because of hemodialysis (n=4), kidney transplantation (n=8), a recent myocardial infarction (n=1), and a recent stroke (n=2). Baseline characteristics of the 252 patients with PAD (mean age, 66±11 years) are shown in Table 1 . In 38 (15%) patients, ankle-brachial index was not measured because PAD had already been established by imaging of the lower arteries (n=12) or a revascularization procedure (n=26) had been performed directly. Mean ankle-brachial index was 0.57±0.15. Seventy-four (29%) patients had diabetes mellitus and 85 (34%) patients had an impaired glucose tolerance. A total of 112 (44%) had a history of cardiovascular disease (CAD, cerebrovascular disease [CVD] or abdominal aortic aneurysm). Mean SAF of the patients with PAD was 2.76±0.66 arbitrary units. Tertiles of SAF ranged between 1.23 and 2.43 (first tertile), 2.43 and 2.97 (second tertile), and 2.97 and 4.58 (third tertile) arbitrary units. As expected, age and diabetes mellitus, as well as the presence of a history of cardiovascular diseases (particularly CVD), increased significantly with each tertile of SAF. In patients with diabetes mellitus, HbA1c and diabetes mellitus duration increased significantly from the first to the third tertile of SAF. Multivariate linear regression analysis showed that age, current smoking, diabetes mellitus, and a history of CVD were the independent determinants of SAF, whereas sex, overweight, hypertension, the use of lipid-lowering drugs, estimated glomerular filtrating rate (eGFR), and a history of CAD did not independently contribute to SAF ( Table 2 ).
Five-Year Follow-Up
Median follow-up duration was 5.1 (interquartile range, 5.0-5.3) years. Of the 252 patients that were included, 62 (25%) patients died, 3 (1%) patients withdrew consent, and 4 (2%) patients were lost to follow-up. Of the 62 patients that died, 32 (52%) died from a cardiovascular cause and 30 (48%) from a noncardiovascular cause. Cancer was the main reason of noncardiovascular death (n=18). Fatal or nonfatal MACE occurred in 62 (25%) patients ( Table 3) .
The Kaplan-Meier curve ( Figure) shows that all-cause mortality increases by tertiles of SAF: 13% in the first tertile, 20% in the second, and 32% in the third tertile (log-rank, P=0.002). Similarly, fatal or nonfatal MACE increases from 13% in the first tertile of SAF to 24% in the second and 32% in the third tertile (log-rank, P=0.004).
The univariate and multivariate Cox regression analyses of both end points are shown in Table 4 . In the univariate model, a higher SAF was associated with increased risk for all-cause mortality, hazard ratio per unit increase: 2.01; 95% confidence interval, 1.40-2.88; P=0.0002. Other univariate significant determinants were age and the use of lipid-lowering drugs, whereas sex, current smoking, overweight, diabetes mellitus, hypertension, eGFR, and history of CAD or CVD were not significantly associated with outcome. For fatal or nonfatal MACE, the hazard ratio per unit increase of SAF was 1.82; 95% confidence interval, 1.28-2.60; P=0.001 in a univariate model. Only age was another univariate significant determinant, whereas sex, current smoking, overweight, diabetes mellitus, hypertension, the use of lipid-lowering drugs, eGFR, and history of CAD or CVD were not significantly associated with outcome. After adjustment for cardiovascular risk factors and the use of lipid-lowering drugs, the hazard ratio for all-cause mortality per unit increase of SAF was 1.63 (95% confidence interval, 1.13-2.34), P=0.009. Similarly, the hazard ratio for fatal or nonfatal MACE was 1.50 (95% confidence interval, 1.01-2.17), P=0.03.
Discussion
Our study shows that SAF, as a measure of AGEs deposition, is associated with all-cause mortality and with fatal or nonfatal MACE in patients with PAD. Also after adjustment for cardiovascular risk factors, the use of lipid-lowering drugs, and cardiovascular morbidity, a higher SAF is associated with increased risk for these end points.
SAF as Risk Marker
Earlier, SAF was associated with 3-year all-cause mortality and with cardiovascular mortality in patients on hemodialysis. 14 13 These conditions are typically characterized by increased oxidative or glycemic stress, thereby accelerating the formation of AGEs. However, in the present study, no association between diabetes mellitus and both end points was found. Likewise, eGFR was not associated with both end points. The present study demonstrates that SAF is 
AGEs in Atherosclerotic Disease
Increased levels of AGEs have been found in serum of patients after a myocardial infarction. 7 Tissue accumulation of AGEs, measured by SAF, was increased in patients with acute myocardial infarction and after a stroke. 8, 15 Furthermore, a high level of the serum AGE pentosidine indicated poor outcomes 30 days after acute ischemic stroke. 16 Recently, we showed that accumulation of tissue AGEs is increased in patients with PAD as compared with controls, independently of cardiovascular risk factors and morbidity. 10 Earlier, we found that SAF was increased in patients with carotid artery stenosis although this increase was confined to the patients with concomitant PAD. 17 In PAD, increased oxidative stress may contribute to the formation and progression of the atherosclerotic process. A recent study showed that specific oxidative biomarkers (oxidized phospholipids) are increased in patients with PAD. 18 In summary, these studies suggest a role of AGEs in atherosclerotic disease irrespective of diabetes mellitus or renal insufficiency.
Study Strengths and Limitations
The main strengths of our study are the low number of patients lost to follow-up (n=4; 2%) and duration of follow-up (median, 5.1 years). However, our study has several limitations. Because our University Hospital is a secondary and tertiary referral center, patients with severe PAD or more cardiovascular morbidity may have been selected. Consequently, the high 5-year event rate may be overestimated. Still, studies mentioned in American College of Cardiology/American Heart Association guidelines also show high 5-year event rate of 20% for nonfatal cardiovascular events (myocardial infarction or stroke) and 5% to 30% for mortality, which are similar to our results (12% myocardial infarction, 4% stroke, and 25% all-cause mortality). 2 Another more recent study of ≈3 million patients with PAD showed an even higher fatal or nonfatal event rate that may be explained by the population that was studied. 3 In that study, only patients that were hospitalized for PAD were studied in contrast with our patients that visited the outpatient clinic.
The high percentages of patients with hypertension or the use of lipid-lowering drugs in the patients with PAD may be explained by the fact that antihypertensive or lipid-lowering drugs may have been prescribed as secondary cardiovascular prevention measures rather than because of the presence of hypertension or hypercholesterolemia. Certain antihypertensive and lipid-lowering drugs may affect AGEs metabolism. 19, 20 However, (multivariate) linear regression analysis of SAF does not suggest such an effect in our cohort. Stratification of the results of the Cox regression analyses by the use of these drugs would have been interesting. Unfortunately, the low number of patients and events in the subgroups of patients that did not use antihypertensive or lipid-lowering drugs were too small to allow such analyses to be meaningful.
A major limitation of the use of SAF by the AGE Reader to measure AGEs level is that it cannot be used in all types of skin. For a valid measurement of SAF, the reflectance of excitation light has to be ≥6%. 21 Strong-pigmented skin type absorbs too much excitation light (resulting in a reflectance of <6%) and emitted fluorescent light. In practice, the AGE Reader can be used up to skin color Fitzpatrick type V. Consequently, the AGE Reader is suitable for most racial groups, except part of subjects of Sub-Saharan African or Afro-American descent.
Finally, although the AGE Reader has been validated against AGEs content of skin biopsies, we do not know the strength of the correlation between SAF and actual level of AGEs in the atheroma of affected arteries. Such a study is yet to be performed. Importantly, 1 study reported an association between SAF and the collagenase digestible collagen fraction in leftover vein graft material from coronary bypass graft operations as measure of AGEs content. 22 In addition, several Univariate and backward multivariate regression analyses for both end points. For sex, female is the reference. CAD indicates coronary artery disease; CI, confidence interval; CVD, cerebrovascular disease; eGFR, estimated glomerular filtrating rate; HR, hazard ratio; and MACE, major adverse cardiovascular events. studies have shown a positive association between SAF and structural and functional arterial properties, such as intima media thickness and pulse wave velocity. 22, 23 Conclusions SAF, as a measure of tissue accumulation of AGEs, is independently associated with all-cause mortality and fatal or nonfatal MACEs in patients with PAD after a 5-year follow-up. This endorses the concept of an important role of AGEs in generalized atherosclerosis, beyond the conditions of diabetes mellitus or renal insufficiency. Future study should investigate whether measurement of SAF can improve the identification of patients with PAD at highest risk for mortality and fatal or nonfatal MACE and whether subsequent intensified treatment of risk factors can improve prognosis.
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